Drug intelligence / Profile preview

PR51

Development stage: Preclinical
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PR51 is a hexavalent combination vaccine formulation developed by Merck Sharp & Dohme LLC. It is designed to provide immunity against Haemophilus influenzae type b, Hepatitis B, Diphtheria, Tetanus, Pertussis, and Poliovirus types 1, 2, and 3. The vaccine contains specific antigens, such as PRP-OMPC (for Haemophilus influenzae type b) and HBsAg (for Hepatitis B), along with diphtheria toxoid, tetanus toxoid, a 5-component acellular pertussis vaccine, and inactivated poliovirus types 1, 2, and 3. Different formulations of PR51, varying in the dosage of PRP-OMPC and HBsAg, are being evaluated for their safety, tolerability, and immunogenicity.

Targets

PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)

Beyond the preview

Go deeper on PR51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR51.

Explore the full profile